Indeed, in a clinical study combining ADI-PEG20 with nab-paclitaxel and gemcitabine in pancreatic cancer, objective results were observed in both ASS1-proficient and -deficient patients48. This evidence concerns the gene ASS1 and familial pancreatic carcinoma.